A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL

Yue Tan; Haodong Cai; Chuo Li; Biping Deng; Weiliang Song; Zhuojun Ling; Guang Hu; Yongkun Yang; Panpan Niu; Guangrong Meng; Wei Cheng; Jinlong Xu; Jiajia Duan; Zelin Wang; Xinjian Yu; Xiaoming Feng; Jianfeng Zhou; Jing Pan

doi:10.1038/s41408-021-00465-9

A novel full-human CD22-CAR T cell therapy with potent activity against CD22^low B-ALL

Blood Cancer J. 2021 Apr 10;11(4):71. doi: 10.1038/s41408-021-00465-9.

Authors

Yue Tan^#^{1

2}, Haodong Cai^#³, Chuo Li^#², Biping Deng⁴, Weiliang Song⁵, Zhuojun Ling⁵, Guang Hu⁶, Yongkun Yang⁶, Panpan Niu⁶, Guangrong Meng⁶, Wei Cheng⁶, Jinlong Xu⁵, Jiajia Duan⁵, Zelin Wang⁵, Xinjian Yu⁷, Xiaoming Feng^{8

9}, Jianfeng Zhou¹⁰, Jing Pan¹¹

Affiliations

¹ State Key Laboratory of Experimental Hematology, Boren Biotherapy Translational Laboratory, Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
³ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
⁴ Cytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
⁵ Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
⁶ Nanjing Iaso Biotherapeutics Co. Ltd, Nanjing, 210000, China.
⁷ Medical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
⁸ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. [email protected].
⁹ Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China. [email protected].
¹⁰ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. [email protected].
¹¹ State Key Laboratory of Experimental Hematology, Boren Biotherapy Translational Laboratory, Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China. [email protected].

^# Contributed equally.

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Animals
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Child
Child, Preschool
Humans
Immunotherapy, Adoptive / adverse effects
Immunotherapy, Adoptive / methods*
Jurkat Cells
K562 Cells
Mice
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Chimeric Antigen / therapeutic use*
Sialic Acid Binding Ig-like Lectin 2 / antagonists & inhibitors
Sialic Acid Binding Ig-like Lectin 2 / immunology*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
CD22 protein, human
Receptors, Chimeric Antigen
Sialic Acid Binding Ig-like Lectin 2